{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:31:14Z","timestamp":1770910274245,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"the Japan Society for the Promotion of Science, JSPS KAKENHI","award":["24592233"],"award-info":[{"award-number":["24592233"]}]}],"content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.canlet.2014.01.027","type":"journal-article","created":{"date-parts":[[2014,2,2]],"date-time":"2014-02-02T11:45:46Z","timestamp":1391341546000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tailored therapeutic strategies for synovial sarcoma: Receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001"],"prefix":"10.1016","volume":"347","author":[{"given":"Hirohiko","family":"Yasui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Naka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Imura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetatsu","family":"Outani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sasagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhito","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Myoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.01.027_b0005","series-title":"Enzinger and Weiss\u2019s Soft Tissue Tumors","author":"Weiss","year":"2008"},{"key":"10.1016\/j.canlet.2014.01.027_b0010","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/stem.452","article-title":"Synovial sarcoma is a stem cell malignancy","volume":"28","author":"Naka","year":"2010","journal-title":"Stem Cells"},{"key":"10.1016\/j.canlet.2014.01.027_b0015","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.clon.2009.07.016","article-title":"Pathology of soft tissue sarcomas","volume":"21","author":"Thway","year":"2009","journal-title":"Clin. Oncol."},{"issue":"May","key":"10.1016\/j.canlet.2014.01.027_b0020","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.2000.18.10.2087","article-title":"Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity","volume":"18","author":"Lewis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/annonc\/mdq394","article-title":"Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors","volume":"22","author":"Krieg","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"MTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2014.01.027_b0035","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.canlet.2014.01.027_b0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"RECORD-1 study group, efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2014.01.027_b0045","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1002\/cncr.24280","article-title":"A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer","volume":"115","author":"Amato","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.01.027_b0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2008.08336.x","article-title":"The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations","volume":"103","author":"Bellmunt","year":"2009","journal-title":"BJU Int."},{"key":"10.1016\/j.canlet.2014.01.027_b0055","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","article-title":"Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163","volume":"27","author":"Ellard","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0065","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"30","author":"Fouladi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0070","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/ijc.25829","article-title":"Phosphatidylinositol-3\u2032-kinase\/AKT signaling is essential in synovial sarcoma","volume":"129","author":"Friedrichs","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.01.027_b0075","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/cncr.28255","article-title":"Prognostic impact of the activation status of the Akt\/mTOR pathway in synovial sarcoma","volume":"119","author":"Setsu","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2014.01.027_b0080","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2003.09.031","article-title":"Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1","volume":"204","author":"Kawai","year":"2004","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2014.01.027_b0085","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.027_b0090","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-05-0068","article-title":"Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor\/insulin receptor substrate-1\/phosphatidylinositol 3-kinase cascade","volume":"4","author":"Shi","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2014.01.027_b0095","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.01.027_b0100","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1158\/0008-5472.CAN-12-1319","article-title":"PDGF receptor alpha is an alternative mediator of rapamycin-induced Akt activation: implications for combination targeted therapy of synovial sarcoma","volume":"72","author":"Ho","year":"2012","journal-title":"Cancer Res."},{"issue":"2007","key":"10.1016\/j.canlet.2014.01.027_b0105","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic\u2013pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2014.01.027_b0110","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/jor.22091","article-title":"A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway","volume":"9","author":"Hosaka","year":"2012","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.canlet.2014.01.027_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00019606-200003000-00001","article-title":"Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma","volume":"9","author":"Antonescu","year":"2000","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.canlet.2014.01.027_b0120","first-page":"135","article-title":"Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients","volume":"62","author":"Ladanyi","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2014.01.027_b0125","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.2004.11.093","article-title":"Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis","volume":"22","author":"Guillou","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2045-3329-3-10","article-title":"Mesenchymal stem cell transformation and sarcoma genesis","volume":"3","author":"Xiao","year":"2013","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.canlet.2014.01.027_b0135","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1634\/stemcells.22-3-405","article-title":"Functional expression of HGF and HGF receptor\/c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing","volume":"22","author":"Neuss","year":"2004","journal-title":"Stem Cells"},{"key":"10.1016\/j.canlet.2014.01.027_b0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.biocel.2006.09.005","article-title":"Platelet-derived growth factor receptor-\u03b1 is a key determinant of smooth muscle \u03b1-actin filaments in bone marrow-derived mesenchymal stem cells","volume":"39","author":"Ball","year":"2007","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2014.01.027_b0145","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1242\/jcs.00417","article-title":"Macroscopic cartilage formation with embryonic stem-cell-derived mesodermal progenitor cells","volume":"116","author":"Nakayama","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2014.01.027_b0150","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/onc.2011.418","article-title":"Reprogramming of mesenchymal stem cells by the synovial sarcoma-associated oncogene SYT-SSX2","volume":"31","author":"Garcia","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.01.027_b0155","first-page":"823","article-title":"Downregulation of SS18\u2013SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo","volume":"36","author":"Takenaka","year":"2010","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2014.01.027_b0160","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/Akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Invest."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T02:44:38Z","timestamp":1648176278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0304383514000652"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.027","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailored therapeutic strategies for synovial sarcoma: Receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}